Close
Close

Impatients N.V. trading as myTomorrows - Graft Vs Host Disease

Partner

Not provided

Rare Disease

Graft Vs Host Disease

Sponsor

Impatients N.V. trading as myTomorrows

Access Program Information

An Early Access Program for patients with steroid refractory acute GvHD after hematopoietic stem cell transplantation. This Program is available for female and male who are recipients of allogenic HSCT and who have been newly diagnosed with acute GvHD. Alpha 1 antitrypsin is being tested in a Phase 2/3 Clinical Study to evaluate the safety and efficacy of Glassia (1-4) as an add-on bio pharmacotherapy to conventional steroid treatment in subjects with acute graft versus host disease with lower gastrointestinal involvement (NCT02956122).

Contact

Contact: Michel van Harten, MD (+31 885253888)

Locations

Free Newsletter